hyperCORE International

Phase 1

Questions?

Phase 1 Capabilities

Nine Phase 1 capable sites in 14 locations in the United States and Canada with 23 Principal Investigators

Collectively conducted 55 Phase 1 trials - 21 were first-in human trials

Overnight capabilities in 8 locations with 107 beds combined. Facilities range from 4,000 to 17,000 SF

On-site pharmacies at 6 sites; PBMC capabilities at 5 sites

Over 2.8 million patients in collective databases; diversity recruitment in Hispanic, Asian, and Black communities

Phase 1 Therapeutics

Cannabis & Psychedelics
Endocrinology
Pain Management
Hematology
Neurology
Men’s Health
Pulmonology
Smoking Cessation
Urology
Nephrology
Devices / Diagnostics
Cardiology
Oncology
NASH Capabilities
Gerontology
Psychiatry
Pediatrics
Podiatry
Dermatology Capabilities
Gynecology
Rheumatology
Nutrition
Vaccine Capabilities
Ophthalmology
Gastroenterology
Immunology
COVID- 19 Capabilities

Phase 1 Testing / Equipment